Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Botulinum toxin (BTX, Botox) is increasingly used as an adjunct therapy to oral steroids in the management of facial paralysis, with positive outcomes. This study aimed to evaluate the additive effect of BTX injection on the non-paralyzed side and propose optimal injection timing for recovery time.
Methods: A total of 48 atraumatic facial paralysis patients who visited Seoul St. Mary's hospital for facial palsy between June 2015 and May 2021 were retrospectively reviewed. Patients were divided into 2 groups: the BTX injection group (BG) and the non-BTX injection group (NBG). We analyzed the recovery rate of facial palsy to H-B grade II or lower in each group, and conducted telephone surveys to collect subjective satisfaction data after BTX injection.
Results: Days of recovery to H-B grade II from symptom onset were 93.0 ± 62 and 68.7 ± 66.6 in NBG and BG, respectively. Early BTX injection (less than 17.5 days from symptom onset) was a prognostic factor for recovery to H-B grade II in less than 1 month (R = 0.935, B = 1.738, p < 0.001). Telephone survey showed subjective satisfaction in all aspects 1 month after BTX injection: function (83.3%), cosmetic (70.9%), and recovery (54.2%).
Conclusion: Early contralateral facial BTX injection can shorten the recovery period of atraumatic facial palsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00405-025-09247-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.
Brain Behav
September 2025
Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.
Methods: This is an open-label, nonrandomized controlled trial.
Engineered Exosomes Complexed with Botulinum Toxin Type A for Enhanced Anti-Aging Effects on Skin.
Biology (Basel)
August 2025
Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory of Brain Science Research Transformation in Tropical Environment of Hainan Province, School of Basic Medicine and Life Sciences, Hainan Medical University, Haikou 571199, China.
Skin aging is commonly characterized by increased wrinkles, loss of elasticity, and hyperpigmentation, significantly affecting personal appearance and quality of life. Although botulinum toxin type A (BTX-A) has been widely applied in cosmetic anti-wrinkle treatments, its intrinsic cytotoxicity limits broader clinical applications. In this study, we developed a novel exosome-based BTX-A composite delivery system designed to synergize the anti-aging properties of exosomes with the wrinkle-reducing effects of BTX-A while reducing toxicity.
View Article and Find Full Text PDFInvestigating the correlation between the blepharospasm disability index and botulinum neurotoxin dosage for benign essential blepharospasm and hemifacial spasm.
Orbit
September 2025
Orbital and Ophthalmic Plastic Surgery Division, Department of Ophthalmology, University of California, Los Angeles, California, USA.
Purpose: The purpose of this study is to evaluate the association between the blepharospasm disability index (BSDI) and botulinum neurotoxin (BTX) dosage for patients affected by either benign essential blepharospasm or hemifacial spasm.
Methods: Cross-sectional cohort study evaluating adult patients diagnosed with benign essential blepharospasm or hemifacial spasm who completed a BSDI evaluation prior to receiving same-day therapeutic BTX injections. Primary outcome measures included BSDI score and number of BTX units.
Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX-A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder.
Neurourol Urodyn
August 2025
Department of Urology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA.
Background: OnabotulinumtoxinA (BTX-A) decreases urge urinary incontinence (UUI) and improves quality of life for patients with idiopathic overactive bladder (IOAB) and neurogenic lower urinary tract dysfunction (NLUTD). Limited research exists optimizing injection techniques for higher doses (200- or 300-units) of BTX-A in the clinic setting. Optimization with less injections could improve satisfaction and willingness to repeat injections while maintaining effectiveness.
View Article and Find Full Text PDFAtrophy Masseter Recovery by Electrical Stimulation Mediated M2-Like Macrophage Polarisation via JAK/PI3K/AKT Pathway.
J Cachexia Sarcopenia Muscle
August 2025
College & Hospital of Stomatology, Anhui Medical University, Key Lab. of Oral Diseases Research of Anhui Province, Hefei, China.
Background: Atrophy of the masseter muscle can result in an aged facial appearance and diminished chewing function. Electrical stimulation (ES) is known for its ability to facilitate tissue healing and functional recovery, but its precise role in the repair of atrophic masseter muscles remains incompletely understood.
Methods: We induced masseter muscle atrophy in rats through botulinum toxin (BTX) injection and subsequently treated the animals with or without ES.